Heparhizine

Composition

Active substances:
Each ampoule contains:

• Monoammonium glycyrrhizinate equivalent to glycyrrhizin – 40 mg
• Glycine – 400 mg
• L-cysteine hydrochloride – 20 mg

Excipients:

• Anhydrous sodium sulfite, sodium chloride, water for injection, concentrated ammonia solution.

Dosage Form

Solution for injection.

Physical and chemical properties:
Clear, colorless solution.

Pharmacotherapeutic Group

Drugs used for liver diseases and lipotropic substances. Hepatotropic agents. ATC code: A05BA.

Pharmacological Properties

Pharmacodynamics

Anti-inflammatory and antiallergic effects:
Glycyrrhizin reduces the likelihood of allergic reactions, including the Arthus and Schwartzman phenomena. It inhibits cortisol-induced thymus atrophy and granulation without affecting the hormone's exudative action.

Regulation of enzymatic processes:
Glycyrrhizin binds to phospholipase A2 and lipoxygenase, selectively inhibiting their activation, which disrupts the arachidonic acid cycle and reduces inflammation mediator synthesis.

Immunomodulatory effects:
In vitro studies indicate glycyrrhizin's ability to activate T-cells, induce interferon-γ, stimulate NK cells, and promote the differentiation of extrathymic T-lymphocytes.

Liver protection and regeneration:

• In vitro experiments demonstrate glycyrrhizin's protective effect on hepatocytes.
• Glycyrrhizinic and glycyrrhetinic acids stimulate hepatocyte proliferation.

Antiviral action:
Studies show glycyrrhizin inhibits the spread of viruses in infected animals, demonstrating efficacy against hepatitis and poxvirus infections.

Supportive role of glycine and cysteine:
These components help counteract pseudoaldosteronism associated with prolonged glycyrrhizin use.

Pharmacokinetics

Blood concentration:
After intravenous administration of 80 mg of glycyrrhizin, blood levels peak and decline within 10 hours. Glycyrrhizinic acid is detected 6 hours post-injection and peaks at 24 hours, with elimination within 48 hours.

Urinary excretion:
Approximately 1.2% of the dose is excreted via urine within 27 hours.

Distribution in animal studies:
The highest accumulation is observed in the liver (73%), followed by the kidneys, lungs, heart, and adrenal glands.

Indications

Used to improve liver function in chronic liver diseases.

Contraindications

• Hypersensitivity to components.
• Conditions such as aldosteronism, myopathy, or hypokalemia, as they may worsen.

Interaction with Other Drugs

Diuretics and antihypertensive agents may enhance glycyrrhizin's potassium-depleting effect, increasing the risk of hypokalemia.

Usage and Dosage

Administer 40–60 ml intravenously once daily. The maximum dose should not exceed 100 ml per day.

Adverse Reactions

Frequent side effects include:

• Shock and anaphylaxis (hypotension, loss of consciousness, dyspnea).
• Pseudoaldosteronism: hypokalemia, hypertension, edema.
• Other: rash, nausea, blurred vision, and general malaise.

Storage Conditions

Store at temperatures below 25°C in the original packaging. Keep out of reach of children.

Packaging

Solution for injection in 20 ml ampoules, 10 ampoules per box.

Manufacturer

Beijing Kawin Technology Share-Holding Co., Ltd., Ukraine.